Working closely with the Centers for Disease Control and Prevention, the AMA CPT Editorial Panel
approved a unique CPT code for each of two coronavirus vaccines as well as administration codes
unique to each such vaccine. The new CPT codes clinically
distinguish each coronavirus vaccine for
better tracking, reporting and analysis that supports data-driven planning and allocation. Importantly,
these CPT codes are available prior to the public availability of the vaccines to facilitate updating
of
health care electronic systems across the U.S.
For quick reference, the new
Category I CPT code and descriptors are:
91300
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease
[COVID-19])
vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted,
for intramuscular use
91301
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus
disease [COVID-19])
vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
In accordance with the new vaccine-specific product CPT codes, the CPT Editorial Panel has
worked with the Centers
for Medicare & Medicaid Services (CMS) to create new vaccine
administration codes that are both distinct to each coronavirus vaccine and the specific dose in the
required schedule. This level of specificity is a first for vaccine CPT
codes, but offers the ability to
track each vaccine dose, even when the vaccine product is not reported (e.g. when the vaccine may
be given to the patient for free). These CPT codes report the actual work of administering the
vaccine, in
addition to all necessary counseling provided to patients or caregivers and updating the
electronic record.
For quick reference,
the new vaccine administration CPT codes and long descriptors are:
0001A
Immunization
administration by intramuscular injection of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein,
preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first
dose
0002A
Immunization administration by intramuscular injection of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein,
preservative free, 30
mcg/0.3mL dosage, diluent reconstituted; second dose
0011A
Immunization administration by intramuscular injection of Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP,
spike protein,
preservative free, 100 mcg/0.5mL dosage; first dose
0012A
Immunization administration by intramuscular injection of Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
vaccine, mRNA-LNP, spike protein,
preservative free, 100 mcg/0.5mL dosage; second dose
All the new vaccine-specific CPT codes published in today’s update will be available for use and
effective upon each new coronavirus vaccine receiving
Emergency Use Authorization or approval
from the Food and Drug Administration.
In addition to the long descriptors, short and medium descriptors for the new vaccine-specific CPT
codes can be accessed on the
AMA website, along with several other recent modifications to the
CPT code set that have helped streamline the public health response to the SARS-CoV-2 virus
and
the COVID-19 disease.
If you would like a machine-readable CSV file containing the above information,
click here.